Dear Colleagues, Welcome to my PES monthly President’s Newsletters! I want to begin by expressing my heartfelt gratitude to Dr.…
More Articles
EVOLOCUMAB (REPATHA) Brenda Kohn MD, Dania Al-Hamad MD, Ambika P. Ashraf MD On September 24, 2021, Amgen announced that the FDA approved evolocumab (Repatha) as an adjunct treatment to diet and…
Historical Tidbit : Paul Langerhans (July 25, 1847-July, 20, 1888) Alan D. Rogol MD, Ph.D Paul Langerhans was a German pathologist who studied medicine in Jena and Berlin. While still…
PES Fellow Spotlight: Samuel Cortez, MD I have been committed to working with underserved and marginalized populations throughout my residency at the University of Kansas and medical school in El…
Camille S. Wheeler, MSN, FNP-C, CPN, RN Camille S. Wheeler, MSN, FNP-C, CPN, RN earned her bachelor’s degree in Nursing from Mississippi University for Women in 2001 and her…
John Scott Parks October 14, 1939 – December 23, 2021 It is with great sadness that we announce the passing of John Scott Parks MD, PhD. Parks was an innovative…
As we approach the coming New Year it is hard not to hope that in 2022 all of us will see an improvement in our day to day lives. Indeed,…
Prepared on behalf of the PES Drugs and Therapeutics Committee by Kristal Matlock, MD, Dania Al-Hamad, MD, Vandana Raman, MD and Amit Lahoti, MD FDA approval for Zegalogue (dasiglucagon) marks…
Gajanthan Muthuvel, MD What is your current position/how do you spend your time? I am a third year Pediatric Endocrinology fellow at Cincinnati Children’s Hospital. I’m originally from Oshkosh, WI…
Israel S. Kleiner (April 8, 1885-June 15, 1966) Submitted by Alan D. Rogol, MD, Ph.D Israel Kleiner, a native of New Haven CT, completed his undergraduate and Ph.D (physiologic chemistry,…
Diana Mysliwiec, PA-C, earned her bachelor’s degree in Biobehavioral Health from the Pennsylvania State University in 2007 and her Master of Physician Assistant Studies from Chatham University in 2009. Her…